Skip to main content

Trinity College Dublin, The University of Dublin

Menu Search

Trinity College Dublin By using this website you consent to the use of cookies in accordance with the Trinity cookie policy. For more information on cookies see our cookie policy.

Profile Photo

Professor Ed Lavelle

Prof/ Course Co-Ordinator (Biochemistry)

Head of School (Sch Office - Biochemistry & Immunology)

I have engaged at teaching at many levels in Universities in Ireland and the U.K. In particular, since October 2004 I have worked as a lecturer, senior lecturer and Professor in Immunology in the School of Biochemistry and Immunology at Trinity College Dublin. In addition to delivering lectures and tutorials to junior and senior sophister students, I have also lectured to students enrolled on the MSc courses in Molecular Medicine, Immunology and Translational Oncology. I was also previously engaged in lecturing at TCD and at the University of Nottingham (England). I have supervised student projects from diploma to Masters degree level and have supervised 14 PhD students to completion. I have been President of the Irish Society for Immunology since 2012, organised a number of National and International conferences, chaired sessions on Immunology and vaccines for a number of national and international conferences and acted as a peer reviewer for leading Immunology journals and for funding bodies in both the EU and the USA. Since acquiring my PhD in 1994, my research has been principally in the fields of Immunology and vaccine adjuvant development. The projects I have worked on have included the piscine mucosal immune system, the use of biodegradable micro and nanoparticles as vaccine adjuvants and the evaluation of plant lectins as bioadhesives, immunogens and immunomodulators. During this time I acquired broad expertise that is applicable to the range of projects I am now engaged in and will pursue in the future. In recent years my principal research interest has been the elucidation of the mechanism of action of adjuvants and immunomodulators. In particular I have focused on on particulate vaccine adjuvants including biodegradable microparticles, alum and the cationic polysaccharide chitosan. This work includes basic research into the mechanism by which these systems activate the immune system and more applied work on the optimisation of these adjuvants for use in injectable and mucosal vaccines. The fundamental adjuvant research includes studies into the cell signalling pathways induced by these molecules which will facilitate a better understanding of their mode(s) of action. In addition, over the past number of years my team have worked closely with our collaborators within AMBER to address the potential of novel biomaterials to drive beneficial immune responses underpinning tissue regeneration. Across all of our activities we depend on building and sustaining close collaborations with National and international Academic and industrial collaborators.
  ADENYLYL-CYCLASE ACTIVITY   ADJUVANTS   cAMP   Cell Death   CREB   IL-10   Immune System   Immunity   Immunology, Immunotherapy   Immunophysiology   Inflammation   LECTIN-BINDING   LECTINS   Life Sciences   Nanotechnology   NF-kappaB   Signal Transduction   Signal Transduction (Sensory/Cellular)   SIGNAL-TRANSDUCTION   SIGNAL-TRANSDUCTION PATHWAYS   Toll-Like Receptors   VACCINE   VACCINE EFFICACY   Vaccines
 SFI Research Centre, Advanced Materials and Bioengineering Research (AMBER) centre
 Modulation of innate and adaptive immunity by particulate adjuvants for improved parenteral and mucosal vaccination.
 Advanced Immunization Technologies ADITEC
 HELICOVAXOR (2013), Development of novel mucosal vaccines against Helicobacter pylori infection.
 Targeted delivery of particulate vaccine adjuvants. (2011).

Page 1 of 6
Details Date
Member of the Editorial board (Drug Delivery) for Expert Opinion on Therapeutic Patents (1997-2005). Member of Scientific committee for the 2nd International Workshop in Vaccine Adjuvants and GlycoCongugates (Adjuvant2004), Varadero, Cuba. Member of Scientific committee for the 3nd International Workshop in Vaccine Adjuvants and GlycoCongugates (Adjuvant2006) to be held in Varadero, Cuba (April, 2006). Guest Editor for a special issue of Vaccine on vaccine adjuvants (2005). Member of the Irish Society for Immunology (ISI) committee. Organisation of a session on "Mucosal Immunity" for the 2005 joint meeting of the ISI and the Royal Society of Medicine. Peer reviewer of grants for the National Institutes of Health (NIH) Grand Challenges in Global Health programme (August 2004).
Language Skill Reading Skill Writing Skill Speaking
English Fluent Fluent Fluent
French Medium Medium Medium
Irish Medium Medium Medium
Spanish Basic Basic Basic
Details Date From Date To
Irish Society for Immunology (President) 2005 (member) 2014
European Adjuvant Advisory Group 2007 2008
European Federation of Immunology Societies 2005 2008
Member of the Society for Mucosal Immunology 2006 2014
Tivnan, A., Heilinger, T., Lavelle, E.C. and Prehn, J.H.M. , Advances in immunotherapy for the treatment of glioblastoma., Journal of Neuro-Oncology, 131, (1), 2017, p1-9 , Notes: [PMID:27743144 ], Journal Article, PUBLISHED  TARA - Full Text  DOI
Moore C., Movia D., Smith R., Hanlon D., Lebre F., Lavelle E., Byrne H., Coleman J., Volkov Y., McIntyre J., Industrial grade 2D molybdenum disulphide (MoS2): an in vitro exploration of the impact on cellular uptake, cytotoxicity, and inflammation, 2D Materials, 4, (2), 2017, Journal Article, PUBLISHED  DOI  URL
The role of inflammasomes in adjuvant-driven humoral and cellular immune responses in, editor(s)Virgil E.J.C. Schijns and Derek. T. O'Hagan , Immunopotentiators in Modern Vaccines, Academic Press, 2016, [Muñoz-Wolf, N, McCluskey, S. and Lavelle, E.C. ], Book Chapter, PUBLISHED  Other
Carroll, E.C., Jin, L., Mori, A., Muñoz-Wolf, N., Oleszycka, E., Moran, H.B.T., Mansouri, S., McEntee, C.P., Lambe, E., Agger, E.M., Andersen, P., Cunningham, C., Hertzog, P., Fitzgerald, K.A., Bowie, A.G., Lavelle, E.C., The Vaccine Adjuvant Chitosan Promotes Cellular Immunity via DNA Sensor cGAS-STING-Dependent Induction of Type I Interferons, Immunity, 44, (3), 2016, p597 - 608, Journal Article, PUBLISHED  DOI
Ní Cheallaigh C, Sheedy FJ, Harris J, Muñoz-Wolf N, Lee J, West K, McDermott EP, Smyth A, Gleeson LE, Coleman M, Martinez N, Hearnden CH, Tynan GA, Carroll EC, Jones SA, Corr SC, Bernard NJ, Hughes MM, Corcoran SE, O'Sullivan M, Fallon CM, Kornfeld H, Golenbock D, Gordon SV, O'Neill LA, Lavelle EC, Keane J, A Common Variant in the Adaptor Mal Regulates Interferon Gamma Signaling., Immunity, 44, (2), 2016, p368-79 , Journal Article, PUBLISHED  TARA - Full Text  URL
Oleszycka, E., Moran, H.B.T., Tynan, G.A., Hearnden, C.H., Coutts, G., Campbell, M., Allan, S.M., Scott, C.J. and Lavelle, E.C. , IL-1α and inflammasome-independent IL-1β promote neutrophil infiltration following alum vaccination. , FEBS Journal, 283, (1), 2016, p9 - 24, Journal Article, PUBLISHED  DOI
Muñoz-Wolf N, Lavelle EC., Innate Immune Receptors., Methods Mol Biol., 1417, 2016, p1 - 43, Journal Article, PUBLISHED  DOI
Pandiyan P, Lavelle E.C, Editorial: Immune cells in the mucosa, Frontiers in Immunology, 7, (DEC), 2016, p00657-, Notes: [Export Date: 27 January 2017], Journal Article, PUBLISHED  TARA - Full Text  DOI  URL
Finlay CM, Stefanska AM, Walsh KP, Kelly PJ, Boon L, Lavelle EC, Walsh PT, Mills KH., Helminth Products Protect against Autoimmunity via Innate Type 2 Cytokines IL-5 and IL-33, Which Promote Eosinophilia., Journal of Immunology, 196, (2), 2016, p703-714 , Journal Article, PUBLISHED  DOI
Lebre, F., Hearnden, C.H., Lavelle, E.C., Modulation of Immune Responses by Particulate Materials, Advanced Materials, 2016, 5525-5541 , Journal Article, PUBLISHED  DOI

Page 1 of 11


Award Date
Fellow of Trinity College Dublin 2012
Trinity College Dublin Start-up fund for new lecturers 2006. Amount awarded was €7,500. 2006
Merrion biopharmaceutical Ltd. Support for Summer student 2008. Amount awarded was €1800. 2008
Modulation of intracellular signaling pathways by adjuvants and immunomodulators. The use of bacterial toxins and their derivatives as immunomodulators. Particulates and non-specific bioadhesives as adjuvants and vaccine delivery systems. Plant lectins as mucosal vaccine adjuvants and carriers.